Compile Data Set for Download or QSAR
Report error Found 46 Enz. Inhib. hit(s) with all data for entry = 3163
TargetCytochrome P450 26B1(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM50253810(R115866 | CHEMBL459505 | N-(4-(2-ethyl-1-(1H-1,2,4...)
Affinity DataIC50: 0.460nMAssay Description:Eighteen compounds were tested as potential inhibitors of CYP26A1 and CYP26B1. The formation of 9-cis-4-OH-RA metabolite was monitored and the percen...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 26B1(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM393281(US9963439, R116010)
Affinity DataIC50: 3.10nMAssay Description:Eighteen compounds were tested as potential inhibitors of CYP26A1 and CYP26B1. The formation of 9-cis-4-OH-RA metabolite was monitored and the percen...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 26A1(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM393281(US9963439, R116010)
Affinity DataIC50: 4.30nMAssay Description:Eighteen compounds were tested as potential inhibitors of CYP26A1 and CYP26B1. The formation of 9-cis-4-OH-RA metabolite was monitored and the percen...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 26A1(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM50253810(R115866 | CHEMBL459505 | N-(4-(2-ethyl-1-(1H-1,2,4...)
Affinity DataIC50: 5.10nMAssay Description:Eighteen compounds were tested as potential inhibitors of CYP26A1 and CYP26B1. The formation of 9-cis-4-OH-RA metabolite was monitored and the percen...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 26B1(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM50157605(Liazal | R-75251 | Liarozole | US9963439, Liarozol...)
Affinity DataIC50: 18nMAssay Description:Eighteen compounds were tested as potential inhibitors of CYP26A1 and CYP26B1. The formation of 9-cis-4-OH-RA metabolite was monitored and the percen...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 3A4(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM151585(US8987315, Ketoconazole | US9180183, Ketoconazole ...)
Affinity DataIC50: 20nMAssay Description:Compounds were assessed for inhibition (IC50, n=2) of CYP2C8, CYP2C9 and CYP3A4 in pooled human liver microsomes using selective probe substrates at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetCytochrome P450 3A4(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM393281(US9963439, R116010)
Affinity DataIC50: 120nMAssay Description:Compounds were assessed for inhibition (IC50, n=2) of CYP2C8, CYP2C9 and CYP3A4 in pooled human liver microsomes using selective probe substrates at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 26B1(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM151585(US8987315, Ketoconazole | US9180183, Ketoconazole ...)
Affinity DataIC50: 140nMAssay Description:Eighteen compounds were tested as potential inhibitors of CYP26A1 and CYP26B1. The formation of 9-cis-4-OH-RA metabolite was monitored and the percen...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 3A4(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM393290(US9963439, Tazarotenic acid | DDBEP)
Affinity DataIC50: 140nMAssay Description:Compounds were assessed for inhibition (IC50, n=2) of CYP2C8, CYP2C9 and CYP3A4 in pooled human liver microsomes using selective probe substrates at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 2C8(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM50253810(R115866 | CHEMBL459505 | N-(4-(2-ethyl-1-(1H-1,2,4...)
Affinity DataIC50: 220nMAssay Description:Compounds were assessed for inhibition (IC50, n=2) of CYP2C8, CYP2C9 and CYP3A4 in pooled human liver microsomes using selective probe substrates at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 3A4(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM50253810(R115866 | CHEMBL459505 | N-(4-(2-ethyl-1-(1H-1,2,4...)
Affinity DataIC50: 470nMAssay Description:Compounds were assessed for inhibition (IC50, n=2) of CYP2C8, CYP2C9 and CYP3A4 in pooled human liver microsomes using selective probe substrates at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 2C8(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM50157605(Liazal | R-75251 | Liarozole | US9963439, Liarozol...)
Affinity DataIC50: 480nMAssay Description:Compounds were assessed for inhibition (IC50, n=2) of CYP2C8, CYP2C9 and CYP3A4 in pooled human liver microsomes using selective probe substrates at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 26A1(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM151585(US8987315, Ketoconazole | US9180183, Ketoconazole ...)
Affinity DataIC50: 660nMAssay Description:Eighteen compounds were tested as potential inhibitors of CYP26A1 and CYP26B1. The formation of 9-cis-4-OH-RA metabolite was monitored and the percen...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 2C9(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM50253810(R115866 | CHEMBL459505 | N-(4-(2-ethyl-1-(1H-1,2,4...)
Affinity DataIC50: 680nMAssay Description:Compounds were assessed for inhibition (IC50, n=2) of CYP2C8, CYP2C9 and CYP3A4 in pooled human liver microsomes using selective probe substrates at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 3A4(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM50157724(CHEMBL3787564 | US9963439, Compound B)
Affinity DataIC50: 1.01E+3nMAssay Description:Compounds were assessed for inhibition (IC50, n=2) of CYP2C8, CYP2C9 and CYP3A4 in pooled human liver microsomes using selective probe substrates at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 3A4(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM50265920(4-((5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthal...)
Affinity DataIC50: 1.22E+3nMAssay Description:Compounds were assessed for inhibition (IC50, n=2) of CYP2C8, CYP2C9 and CYP3A4 in pooled human liver microsomes using selective probe substrates at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 3A4(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM393295(US9963439, Compound F)
Affinity DataIC50: 1.25E+3nMAssay Description:Compounds were assessed for inhibition (IC50, n=2) of CYP2C8, CYP2C9 and CYP3A4 in pooled human liver microsomes using selective probe substrates at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 2C8(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM151585(US8987315, Ketoconazole | US9180183, Ketoconazole ...)
Affinity DataIC50: 1.56E+3nMAssay Description:Compounds were assessed for inhibition (IC50, n=2) of CYP2C8, CYP2C9 and CYP3A4 in pooled human liver microsomes using selective probe substrates at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 3A4(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM393294(US9963439, Compound E)
Affinity DataIC50: 1.58E+3nMAssay Description:Compounds were assessed for inhibition (IC50, n=2) of CYP2C8, CYP2C9 and CYP3A4 in pooled human liver microsomes using selective probe substrates at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 2C9(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM50157605(Liazal | R-75251 | Liarozole | US9963439, Liarozol...)
Affinity DataIC50: 1.63E+3nMAssay Description:Compounds were assessed for inhibition (IC50, n=2) of CYP2C8, CYP2C9 and CYP3A4 in pooled human liver microsomes using selective probe substrates at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 3A4(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM50157731(CHEMBL3785511 | US9963439, Compound C)
Affinity DataIC50: 1.69E+3nMAssay Description:Compounds were assessed for inhibition (IC50, n=2) of CYP2C8, CYP2C9 and CYP3A4 in pooled human liver microsomes using selective probe substrates at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 2C8(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM393281(US9963439, R116010)
Affinity DataIC50: 1.76E+3nMAssay Description:Compounds were assessed for inhibition (IC50, n=2) of CYP2C8, CYP2C9 and CYP3A4 in pooled human liver microsomes using selective probe substrates at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 26A1(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM50157605(Liazal | R-75251 | Liarozole | US9963439, Liarozol...)
Affinity DataIC50: 1.90E+3nMAssay Description:Eighteen compounds were tested as potential inhibitors of CYP26A1 and CYP26B1. The formation of 9-cis-4-OH-RA metabolite was monitored and the percen...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 3A4(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM50052414(4-(1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthale...)
Affinity DataIC50: 2.30E+3nMAssay Description:Compounds were assessed for inhibition (IC50, n=2) of CYP2C8, CYP2C9 and CYP3A4 in pooled human liver microsomes using selective probe substrates at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 2C9(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM151585(US8987315, Ketoconazole | US9180183, Ketoconazole ...)
Affinity DataIC50: 2.57E+3nMAssay Description:Compounds were assessed for inhibition (IC50, n=2) of CYP2C8, CYP2C9 and CYP3A4 in pooled human liver microsomes using selective probe substrates at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 3A4(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM393287(US9963439, Compound D)
Affinity DataIC50: 2.60E+3nMAssay Description:Compounds were assessed for inhibition (IC50, n=2) of CYP2C8, CYP2C9 and CYP3A4 in pooled human liver microsomes using selective probe substrates at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 3A4(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM393293(US9963439, Compound A)
Affinity DataIC50: 2.95E+3nMAssay Description:Compounds were assessed for inhibition (IC50, n=2) of CYP2C8, CYP2C9 and CYP3A4 in pooled human liver microsomes using selective probe substrates at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 3A4(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM50265951(ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-...)
Affinity DataIC50: 3.15E+3nMAssay Description:Compounds were assessed for inhibition (IC50, n=2) of CYP2C8, CYP2C9 and CYP3A4 in pooled human liver microsomes using selective probe substrates at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 26A1(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM50157731(CHEMBL3785511 | US9963439, Compound C)
Affinity DataIC50: 3.25E+3nMAssay Description:Eighteen compounds were tested as potential inhibitors of CYP26A1 and CYP26B1. The formation of 9-cis-4-OH-RA metabolite was monitored and the percen...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 3A4(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM50032219(4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2...)
Affinity DataIC50: 3.70E+3nMAssay Description:Compounds were assessed for inhibition (IC50, n=2) of CYP2C8, CYP2C9 and CYP3A4 in pooled human liver microsomes using selective probe substrates at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 26A1(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM393287(US9963439, Compound D)
Affinity DataIC50: 3.90E+3nMAssay Description:Eighteen compounds were tested as potential inhibitors of CYP26A1 and CYP26B1. The formation of 9-cis-4-OH-RA metabolite was monitored and the percen...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 26A1(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM50157724(CHEMBL3787564 | US9963439, Compound B)
Affinity DataIC50: 4.40E+3nMAssay Description:Eighteen compounds were tested as potential inhibitors of CYP26A1 and CYP26B1. The formation of 9-cis-4-OH-RA metabolite was monitored and the percen...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 26A1(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM50032219(4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2...)
Affinity DataIC50: 5.60E+3nMAssay Description:Eighteen compounds were tested as potential inhibitors of CYP26A1 and CYP26B1. The formation of 9-cis-4-OH-RA metabolite was monitored and the percen...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 2C9(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM393281(US9963439, R116010)
Affinity DataIC50: 5.76E+3nMAssay Description:Compounds were assessed for inhibition (IC50, n=2) of CYP2C8, CYP2C9 and CYP3A4 in pooled human liver microsomes using selective probe substrates at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 26A1(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM50052414(4-(1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthale...)
Affinity DataIC50: 6.50E+3nMAssay Description:Eighteen compounds were tested as potential inhibitors of CYP26A1 and CYP26B1. The formation of 9-cis-4-OH-RA metabolite was monitored and the percen...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 26A1(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM393290(US9963439, Tazarotenic acid | DDBEP)
Affinity DataIC50: 7.60E+3nMAssay Description:Eighteen compounds were tested as potential inhibitors of CYP26A1 and CYP26B1. The formation of 9-cis-4-OH-RA metabolite was monitored and the percen...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 26A1(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM393295(US9963439, Compound F)
Affinity DataIC50: 9.90E+3nMAssay Description:Eighteen compounds were tested as potential inhibitors of CYP26A1 and CYP26B1. The formation of 9-cis-4-OH-RA metabolite was monitored and the percen...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 3A4(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM50157605(Liazal | R-75251 | Liarozole | US9963439, Liarozol...)
Affinity DataIC50: 1.00E+4nMAssay Description:Compounds were assessed for inhibition (IC50, n=2) of CYP2C8, CYP2C9 and CYP3A4 in pooled human liver microsomes using selective probe substrates at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 26A1(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM50265920(4-((5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthal...)
Affinity DataIC50: 1.05E+4nMAssay Description:Eighteen compounds were tested as potential inhibitors of CYP26A1 and CYP26B1. The formation of 9-cis-4-OH-RA metabolite was monitored and the percen...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 3A4(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM50061625(4-[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthal...)
Affinity DataIC50: 1.07E+4nMAssay Description:Compounds were assessed for inhibition (IC50, n=2) of CYP2C8, CYP2C9 and CYP3A4 in pooled human liver microsomes using selective probe substrates at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 26A1(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM50061625(4-[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthal...)
Affinity DataIC50: 1.31E+4nMAssay Description:Eighteen compounds were tested as potential inhibitors of CYP26A1 and CYP26B1. The formation of 9-cis-4-OH-RA metabolite was monitored and the percen...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 26A1(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM393289(US9963439, BMS961)
Affinity DataIC50: 1.48E+4nMAssay Description:Eighteen compounds were tested as potential inhibitors of CYP26A1 and CYP26B1. The formation of 9-cis-4-OH-RA metabolite was monitored and the percen...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 3A4(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM36810(BMS753 | US9963439, BMS753)
Affinity DataIC50: 2.90E+4nMAssay Description:Compounds were assessed for inhibition (IC50, n=2) of CYP2C8, CYP2C9 and CYP3A4 in pooled human liver microsomes using selective probe substrates at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 3A4(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM393289(US9963439, BMS961)
Affinity DataIC50: 3.90E+4nMAssay Description:Compounds were assessed for inhibition (IC50, n=2) of CYP2C8, CYP2C9 and CYP3A4 in pooled human liver microsomes using selective probe substrates at ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 26A1(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM36810(BMS753 | US9963439, BMS753)
Affinity DataIC50: 4.02E+4nMAssay Description:Eighteen compounds were tested as potential inhibitors of CYP26A1 and CYP26B1. The formation of 9-cis-4-OH-RA metabolite was monitored and the percen...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetCytochrome P450 26A1(Human)
University of Washington Through Its Center For Commercialization

US Patent
LigandPNGBDBM393294(US9963439, Compound E)
Affinity DataIC50: 4.25E+4nMAssay Description:Eighteen compounds were tested as potential inhibitors of CYP26A1 and CYP26B1. The formation of 9-cis-4-OH-RA metabolite was monitored and the percen...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent